คำอธิบาย

Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading.

เหมาะสำหรับ

Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment และ Long Term biologic therapy

คำอธิบาย

Skyrizi is an FDA-approved prescription biologic medication and interleukin-23 (IL-23) inhibitor. It is used to treat adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease or ulcerative colitis. The medication is available in several forms, including a 150 mg/mL single-dose prefilled pen or syringe for subcutaneous injection, as well as an intravenous (IV) infusion for induction and an on-body injector for maintenance dosing. As a targeted immunology therapy, it helps reduce inflammation by blocking specific proteins in the body.

เหมาะสำหรับ

Moderate To Severe plaque psoriasis, Active psoriatic arthritis, Crohn's disease management, Ulcerative colitis treatment และ Biologic therapy seekers

คำอธิบาย

Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia.

เหมาะสำหรับ

Regional medical reference, Singapore Based patients และ Biologic therapy information